MAXCYTE, INC. (MXCT) Form 8-K — Oct 14, 2026
MaxCyte (NASDAQ: MXCT) announced preliminary, unaudited Q3 2026 revenue, with core business revenue of approximately $8.1 million, up 26% year-over-year, plus more than $1.0 million of Strategic Platform License (SPL) Program-related revenue including a $1.0 million milestone. The company raised its full-year 2026 revenue guidance to approximately $34 million from the prior $30-32 million range, with core business revenue now expected at approximately $28 million and SPL-related revenue at approximately $6 million.
Key figures
- Revenue
- approximately $9.1 million total Q3 2026 (core business ~$8.1 million plus >$1.0 million SPL-related)
- Guidance
- FY2026 total revenue ~$34 million (prior $30-32M); core business ~$28M (prior $25-27M); SPL-related ~$6M (prior ~$5M)
- Revenue Yoy
- core business revenue up 26% vs Q3 2025
- Spl q3 revenue
- 1000000
- Core q3 revenue
- 8100000
- Fy spl guidance
- 6000000
- Fy core guidance
- 28000000
- H2 core growth yoy
- approximately 15%
- Milestone revenue q3
- 1000000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.